Fundz

Gensight Biologics Secures €12 Million Financing Through A Premium Convertible Notes Issuance To An Institutional Investor And Provides Business Update

PRIVATEDec 23, 2022

Amount Raised

€12 Million

Round Type

Convertible Note

ParisBiotechnologyHealth CareTherapeuticsBiopharma

Investors

European Investment BankKreos Capital Vi LimitedHeights Capital

Description

Regulatory News:

Who to call at GenSight Biologics, and when

A new round usually means GenSight Biologics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day GenSight Biologics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at GenSight Biologics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

GenSight Biologics

Location

Paris, Ile-de-France, France

About

GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment GenSight Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

4 contacts
Verified contactsScott J., Chief Technology Officer hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for GenSight Biologics's next move

See what Strategic adds

GenSight Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.